Trial Profile
An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK; Novartis
- 22 Apr 2021 Status changed from active, no longer recruiting to completed.
- 16 Mar 2021 Planned End Date changed from 28 Feb 2021 to 30 Mar 2021.
- 11 Dec 2020 Planned End Date changed from 31 Dec 2020 to 28 Feb 2021.